The novel p53 isoform "delta p53" is a misfolded protein and does not bind the p21 promoter site

被引:7
|
作者
Garcia-Alai, Maria M. [1 ]
Tidow, Henning [1 ]
Natan, Eviatar [1 ]
Townsley, Fiona M. [1 ]
Veprintsev, Dmitry B. [1 ]
Fersht, Alan R. [1 ]
机构
[1] MRC, Ctr Prot Engn, Cambridge CB2 0QH, England
基金
英国医学研究理事会;
关键词
protein structure/folding; structure/function studies; DNA-binding domains; dominant-negative mutation;
D O I
10.1110/ps.036996.108
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The tumor suppressor p53 can be expressed as different isoforms because of promoter selection and mRNA editing. One isoform, "delta p53'' (Delta p53), results from what would be an unusual alternative splicing of exons 7/8 of the p53 gene, conserving the reading frame and generating a novel protein with proposed transcriptional activity essential for the intra S-phase checkpoint. Here, we show that the deletion of the 66 residues that correspond to strand beta 10 and the C-terminal helix of the core domain and the interconnecting linker to the tetramerization domain occurring in the Delta p53 isoform leads to a misfolded and unstable protein, prone to form soluble aggregates, which does not bind the p21 promoter site. The complex of coexpressed Delta p53 and flp53 is soluble in vitro and binds poorly to DNA. Our results provide a structural explanation for the dominant-negative effect of Delta p53 and its lack of transcriptional activity.
引用
收藏
页码:1671 / 1678
页数:8
相关论文
共 50 条
  • [31] Expression of p53, p21 and cyclin D1 in penile cancer: p53 predicts poor prognosis
    Gunia, Sven
    Kakies, Christoph
    Erbersdobler, Andreas
    Hakenberg, Oliver W.
    Koch, Stefan
    May, Matthias
    JOURNAL OF CLINICAL PATHOLOGY, 2012, 65 (03) : 232 - 236
  • [32] p53β isoform modulates differentially p53 transcriptional activity in response to stress
    K Fernandes
    JC Bourdon
    Breast Cancer Research, 10
  • [33] p53β isoform modulates differentially p53 transcriptional activity in response to stress
    Fernandes, K.
    Bourdon, J. C.
    BREAST CANCER RESEARCH, 2008, 10 (Suppl 2) : S9 - S9
  • [34] Living with p53, dying of p53
    Aylon, Yael
    Oren, Moshe
    CELL, 2007, 130 (04) : 597 - 600
  • [35] Alteration of p53 and p21 during hepatocarcinogenesis in tree shrews
    Jian-Jia Su
    Yuan Li
    Ke-Chen Ban
    Liu-Liang Qin
    Chun Yang
    Chao Ou
    Xiao-Xian Duan
    Hui-Yun Wang
    Rui-Qi Yang
    Young-Lk Lee
    World Journal of Gastroenterology, 2004, (24) : 3559 - 3563
  • [36] Prognostic and predictive value of p53 and p21 in breast cancer
    Richard M. Elledge
    D. Craig Allred
    Breast Cancer Research and Treatment, 1998, 52 : 79 - 98
  • [37] Role of p21 and its relationship to p53 in breast carcinomas
    Scott, KA
    Walker, RA
    JOURNAL OF PATHOLOGY, 1997, 181 : A23 - A23
  • [38] p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer
    Roh, JW
    Kim, JW
    Park, NH
    Song, YS
    Park, IA
    Park, SY
    Kang, SB
    Lee, HP
    GYNECOLOGIC ONCOLOGY, 2004, 93 (02) : 499 - 505
  • [39] Alteration of p53 and p21 during hepatocarcinogenesis in tree shrews
    Su, Jian-Jia
    Ban, Ke-Chen
    Li, Yuan
    Qin, Liu-Liang
    Wang, Hui-Yun
    Yang, Chun
    Ou, Chao
    Duan, Xiao-Xian
    Lee, Young-Lk
    Yang, Rui-Qi
    WORLD JOURNAL OF GASTROENTEROLOGY, 2004, 10 (24) : 3559 - 3563
  • [40] p21/p53, cellular growth control and genomic integrity
    El-Deiry, WS
    CYCLIN DEPENDENT KINASE (CDK) INHIBITORS, 1998, 227 : 121 - 137